Lantheus (NASDAQ:LNTH) Updates Q1 2020 Pre-Market Earnings Guidance

Lantheus (NASDAQ:LNTH) issued an update on its first quarter 2020
Pre-Market earnings guidance on Tuesday morning. The company provided earnings per share guidance of 0.25-0.27 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.03. The company issued revenue guidance of $89-91 million, compared to the consensus revenue estimate of $100.98 million.Lantheus also updated its FY 2020
Pre-Market guidance to 1.34-1.40 EPS.

LNTH traded down $0.39 during trading on Wednesday, reaching $16.30. 699,539 shares of the stock traded hands, compared to its average volume of 405,727. The stock has a market cap of $650.96 million, a price-to-earnings ratio of 18.74 and a beta of 1.43. Lantheus has a fifty-two week low of $15.53 and a fifty-two week high of $29.80. The company has a debt-to-equity ratio of 1.84, a current ratio of 2.59 and a quick ratio of 2.08. The stock’s 50-day simple moving average is $17.76 and its two-hundred day simple moving average is $20.46.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings data on Tuesday, February 25th. The medical equipment provider reported $0.34 EPS for the quarter, topping analysts’ consensus estimates of $0.30 by $0.04. The business had revenue of $89.35 million for the quarter, compared to analyst estimates of $90.62 million. Lantheus had a return on equity of 46.58% and a net margin of 10.02%. The firm’s revenue for the quarter was up 3.6% on a year-over-year basis. During the same period in the previous year, the company posted $0.29 earnings per share. Research analysts anticipate that Lantheus will post 1 earnings per share for the current fiscal year.

Several brokerages have recently commented on LNTH. BidaskClub raised Lantheus from a strong sell rating to a sell rating in a report on Wednesday. ValuEngine upgraded shares of Lantheus from a sell rating to a hold rating in a research report on Saturday, February 15th. One analyst has rated the stock with a sell rating, two have issued a hold rating and one has assigned a buy rating to the company. Lantheus currently has a consensus rating of Hold and an average target price of $29.00.

In other Lantheus news, Director Sam R. Leno sold 11,508 shares of the stock in a transaction dated Friday, December 13th. The shares were sold at an average price of $20.30, for a total value of $233,612.40. Following the transaction, the director now directly owns 38,072 shares of the company’s stock, valued at approximately $772,861.60. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Mary Anne Heino sold 9,898 shares of the stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $16.06, for a total transaction of $158,961.88. Following the completion of the transaction, the chief executive officer now directly owns 556,014 shares in the company, valued at $8,929,584.84. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 47,017 shares of company stock valued at $926,373. Company insiders own 2.60% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, a microbubble contrast agent used in ultrasound exams of the heart; and TechneLite, a technetium generator that provides the nuclear material used in nuclear medicine procedures.

Further Reading: Derivative

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with's FREE daily email newsletter.